156 / 1851
Triple negative
33
Subtypes according to clinical-
pathological and genomic risk
assessment
Treatment
recommendation
De-escalation
Escalation
Ductal triple negative
pT1a node negative
Higher T and N stage
Neoadjuvant therapy for
stage II or III is suggested
as initial treatment
approach.
Chemotherapy should
include anthracycline and
taxanes
No routine adjuvant
chemotherapy for
stage pT1a pN0.
Dose-dense
adjuvant
chemotherapy
preferred by only a
minority of the
consensus panel
No consensus on post-
neoadjuvant treatment in
case of residual disease.
In BRCA1/2 associated
cancers, the Panel was
evenly split on whether to
recommend (neo)-adjuvant
platinum chemotherapy
though agreed that such
patients should receive
alkylating chemotherapy.